Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
about
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usageThe future direction and unmet needs of transplant immunosuppression.Safety of mTOR inhibitors in adult solid organ transplantation.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial.Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.Effects of anti-human T lymphocyte immune globulins in patients: new or old.Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.Infectious Complications Following Small Bowel Transplantation.Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantationNegative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression?
P2860
Q26784305-26C5FC52-320F-45B3-8B59-E94F147C7886Q30277037-BABB2276-173F-450D-AEA9-FA0BD053FD8BQ38669190-7205DB48-91AB-4F8F-A1A5-930C24264221Q38711763-47F8230C-9EBB-4186-A0F2-9BA4F64A32EEQ38747503-EB00647E-8001-49A0-A03C-225EAF298CFBQ38914374-2B2F86CD-AA54-4FBF-8DD0-2D45D576968AQ38947867-8AC6A45F-C7E6-4120-BA9A-4D2BA02215B0Q40141033-F86741FE-4279-403B-B0D6-F9A9B33F3491Q40267366-A3BC0FB2-3105-4837-A28F-EBAF4251D7AAQ40483831-296165C2-FE6E-4F32-8A0E-8FCB4F46CD17Q40711913-80F70E95-2CB4-4265-9A75-1FF6F5E8BFE5Q40856064-8CB670BA-430D-4811-A5D0-629A0E4D66CDQ40912977-4CFB5D6F-D296-46CB-A684-BCD6BAAECC06Q50997883-5B9F174D-49E8-444F-9414-09EFCF223758Q56963171-B4689E34-2134-45E7-8AD1-63ADB31F2EABQ58796854-B590F04E-A89E-44F9-9968-B6830E064B2C
P2860
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Reduced Incidence of Cytomegal ...... and Reduced Tacrolimus Doses.
@en
type
label
Reduced Incidence of Cytomegal ...... and Reduced Tacrolimus Doses.
@en
prefLabel
Reduced Incidence of Cytomegal ...... and Reduced Tacrolimus Doses.
@en
P2093
P2860
P356
P1476
Reduced Incidence of Cytomegal ...... s and Reduced Tacrolimus Doses
@en
P2093
A Ferreira
H Tedesco-Silva
M Cristelli
M Gerbase-DeLima
N Oliveira
T Sandes-Freitas
P2860
P304
P356
10.1111/AJT.13327
P407
P577
2015-05-18T00:00:00Z